Cost of therapy

Zharova M.E.

Zharova M.E.

National Medical Research Center for Transplantology and Endocrinology

SPIN RSCI: 4882-3634
Scopus AuthorID: 57221727820
ORCID: 0000-0002-8325-5927

Cost of therapy

Authors:

Zharova M.E.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2026;(1‑2): 40‑58

Read: 121 times

Contact the author

Table of contents

To cite this article:

Zharova ME. Cost of therapy. Non Nocere. New Therapeutic Journal. 2026;(1‑2):40‑58. (In Russ.)

Использование инфографики авторами научных работ

References:

Drug-induced liver injury (DILI): clinical guidelines index / Ministry of Health of the Russian Federation. – Electronic data. – 2025. – ID: 747_2 (accessed: 12.01.2026). https://cr.minzdrav.gov.ru/view-cr/747_2
Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol. 2020 Oct;94(10):3381-3407. https://doi.org/10.1007/s00204-020-02885-1
Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Therap Adv Gastroenterol. 2023 Mar 21;16:17562848231163410. https://doi.org/10.1177/17562848231163410
Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-1065. https://doi.org/10.1002/hep.32689
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222-1261. https://doi.org/10.1016/j.jhep.2019.02.014
Tkachenko P.E., Ivashkin V.T., Maevskaya M.V. Clinical guidelines for the correction of hepatotoxicity induced by antitumor therapy. Malignant tumors. 2021;11(3s2):64-77. https://doi.org/10.18027/2224-5057-2021-11-3s2-40
Ahmad J, Rossi S, Rodgers SK, et al. Sclerosing Cholangitis Like Changes on Magnetic Resonance Cholangiography in Patients with Drug Induced Liver Injury. Clin Gastroenterol Hepatol. 2019 Mar;17(4):789-790. https://doi.org/10.1016/j.cgh.2018.06.035
Volynets GV, Nikitin AV, Skvortsova TA, Kokiashvili VS. Drug-induced autoimmune-like hepatitis. Russian Journal of Evidence-Based Gastroenterology. 2024;13(1):58-65. (In Russ.) https://doi.org/10.17116/dokgastro20241301158
Simental-Mendía M, Sánchez-García A, Simental-Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol. 2020 Aug;86(8):1476-1488. https://doi.org/10.1111/bcp.14311
Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. Front Pharmacol. 2021 Oct 27;12:744488. https://doi.org/10.3389/fphar.2021.744488
Vincenzi B, Russo A, Terenzio A, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018 Oct;130:70-77. https://doi.org/10.1016/j.critrevonc.2018.06.019
Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003 Nov-Dec;23(6D):5173-5179.
Snegovoy A.V., Larionova V.B., Zeynalova P.A., Manyuk L.V., Kreynina Yu.M., Kagonia L.M. Final results of the prospective multicenter program p12-717 (use of Heptral in chronic liver disease caused by drug-induced liver damage due to chemotherapy). Bulletin of the N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences. 2016;27(2):142-156.
Sukhanov D.S., Pavlova M.V., Vinogradova T.I. Clinical efficacy of infusion solutions based on succinic acid in the treatment of liver damage caused by anti-tuberculosis drugs. Tuberculosis and lung diseases. 2013;8:50-56.